Compare
Enanta Pharmaceuticals Inc vs Spero Therapeutics, Inc. vs Nuvation Bio Inc. vs Rockwell Medical, Inc.
| Latest fiscal year | Enanta Pharmaceuticals Inc ENTA | Spero Therapeutics, Inc. SPRO | Nuvation Bio Inc. NUVB | Rockwell Medical, Inc. RMTI |
|---|---|---|---|---|
| Year ended | 2025-09-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $65.32M | $66.80M | $62.90M | $69.26M |
| Revenue growth (YoY) | -3.4% | +39.2% | +699.0% | -31.8% |
| Gross margin | n/a | n/a | n/a | 16.9% |
| Operating margin | -130.7% | 9.5% | -338.7% | -6.8% |
| Net margin | -125.4% | 12.8% | -325.3% | -7.7% |
| Net income | -$81.89M | $8.57M | -$204.63M | -$5.31M |
| EPS (Diluted) | -$3.84 | $0.15 | -$0.60 | -$0.15 |
| Operating cash flow | -$19.27M | -$12.62M | -$173.43M | -$659.0K |
| Free cash flow | -$32.17M | n/a | n/a | -$1.20M |
| Cash & equivalents | $32.30M | $40.27M | $164.09M | $10.71M |
| Total assets | $280.73M | $68.92M | $594.82M | $57.15M |
| Total liabilities | $216.01M | $9.90M | $289.11M | $20.16M |
| Shareholders' equity | $64.72M | $59.02M | $305.72M | $36.98M |
| Return on year-end equity | -126.5% | 14.5% | -66.9% | -14.4% |
| Shares outstanding | 21.39M | 56.41M | 337.84M | 39.41M |
Revenue, most recent five fiscal years
| Fiscal year | Enanta Pharmaceuticals Inc | Spero Therapeutics, Inc. | Nuvation Bio Inc. | Rockwell Medical, Inc. |
|---|---|---|---|---|
| Latest | $65.32M Ended 2025-09-30 | $66.80M Ended 2025-12-31 | $62.90M Ended 2025-12-31 | $69.26M Ended 2025-12-31 |
| 1 year earlier | $67.64M Ended 2024-09-30 | $47.98M Ended 2024-12-31 | $7.87M Ended 2024-12-31 | $101.49M Ended 2024-12-31 |
| 2 years earlier | $79.20M Ended 2023-09-30 | $103.78M Ended 2023-12-31 | $0 Ended 2023-12-31 | $83.61M Ended 2023-12-31 |
| 3 years earlier | $86.16M Ended 2022-09-30 | $53.51M Ended 2022-12-31 | n/a | $72.81M Ended 2022-12-31 |
| 4 years earlier | $97.07M Ended 2021-09-30 | $18.26M Ended 2021-12-31 | n/a | $61.93M Ended 2021-12-31 |